Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Pfost Dale R
 2. Date of Event Requiring Statement (Month/Day/Year)
03/29/2007		 3. Issuer Name and Ticker or Trading Symbol
eXegenics Inc [EXEG]
(Last)
(First)
(Middle)
EXEGENICS INC., 4400 BISCAYNE BOULEVARD, SUITE 900		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

MIAMI, FL 33137		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $.01 par value 1,687,261
D (1)
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Convertible Preferred Stock   (2)   (2) Common Stock 518,900 $ 0 D  
Warrant (Right to Buy)   (3) 03/27/2017 Common Stock 64,868 $ 0.002 D  
Warrant (Right to Buy)   (3) 03/27/2017 Common Stock 68,852 $ 0.6728 D  
Warrant (Right to Buy)   (3) 03/27/2017 Common Stock 68,852 $ 0.8473 D  
Warrant (Right to Buy)   (3) 03/27/2017 Common Stock 68,852 $ 1.0466 D  
Stock Option (Right to Buy)   (4) 09/24/2014 Series C Convertible Preferred Stock 7,317 $ 31.8 D  
Stock Option (Right to Buy)   (5) 12/11/2013 Common Stock 430,722 $ 0.04 D  
Stock Option (Right to Buy)   (4) 09/24/2014 Common Stock 225,740 $ 0.04 D  
Stock Option (Right to Buy)   (6) 02/15/2015 Common Stock 1,297,357 $ 0.04 D  
Stock Option (Right to Buy)   (7) 11/01/2015 Common Stock 311,365 $ 0.05 D  
Stock Option (Right to Buy)   (8) 01/01/2016 Common Stock 311,365 $ 0.05 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Pfost Dale R
EXEGENICS INC.
4400 BISCAYNE BOULEVARD, SUITE 900
MIAMI, FL 33137		       President  

Signatures

/s/ Dale R. Pfost 03/30/2007
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) 1,081,116 of these shares are owned jointly by Mr. Pfost and his wife.
(2) These shares are currently exercisable and do not expire.
(3) These warrants are currently exercisable.
(4) These options are fully vesed.
(5) 349,657 of these options are presently fully vested. The balance will vest monthly until fully vested in December 2007.
(6) 675,705 of these options are presently fully vested. The balance will vest monthly until fully vested in February 2009..
(7) 103,785 of these options are presently fully vested. The balance will vest monthly until fully vested in November 2009.
(8) 90,814 of these options are presently fully vested. The balance will vest monthly until fully vested in January 2010.
 
Remarks:
All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.